Medical termination of pregnancy.
Christin-Maitre
S
S
Université Pierre et Marie Curie, Service d'Endocrinologie, Hôpital Saint-Antoine, Assistance Publique Hôpitaux de Paris, France.
Bouchard
P
P
Spitz
I M
IM
D000019:Abortifacient Agents / Q000009:adverse effects / Q000494:pharmacology; D000028:Abortion, Induced / Q000009:adverse effects / Q000379:methods*; D000527:Alprostadil / Q000009:adverse effects / Q000031:analogs & derivatives; D000075202:Contraindications; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects; D015735:Mifepristone / Q000009:adverse effects; D011247:Pregnancy / Q000502:physiology; D011374:Progesterone / Q000037:antagonists & inhibitors; D011453:Prostaglandins / Q000009:adverse effects; D014590:Uterine Contraction
D000019:Abortifacient Agents; D004338:Drug Combinations; D011453:Prostaglandins; D015735:Mifepristone; C021182:gemeprost; D011374:Progesterone; D000527:Alprostadil; D008727:Methotrexate